Phase 2 clinical study for patients with dcSSc or PAH
Phase 2 clinical study for patients with diffuse cutaneous systemic sclerosis (dcSSc) or patients with pulmonary arterial hypertension (PAH)
The American company, Cumberland Pharmaceuticals, is conducting a phase 2 clinical study evaluating the safety and effectiveness of a new oral drug product in patients with diffuse cutaneous systemic sclerosis (dcSSc) or patients with pulmonary arterial hypertension (PAH) associated with their scleroderma. The study is open at 6 Scleroderma Centers of Excellence and opening at more centers with active Scleroderma Research programs.
General study information can be found at the study’s NCT website (NCT02682511). Eligible subjects will be reimbursed for their time and travel. If you are interested in learning more, please contact us at 615-627-4121 or firstname.lastname@example.org
At the moment the study is targeted Australia, Canada, South Africa, India and U.S.
news & events
Are you living with diffuse scleroderma?
Would you like to be involved in a clinical study testing a new investigational drug for use in Diffuse Scleroderma?
If so, you may be eligible to take part in the DECODE Scleroderma Study
FESCA is proud to be a partner of a the new This is Living campaign launched last month by Boehringer Ingelheim.
We are happy to share with you our latest newsletter. Read about World Scleroderma Day 2021, projects, our next world congress and more.